Contact
searchSearch
HMP Global
Login

Psych Congress Network

Latest News, Insights, and Quizzes

Michael Asbach
Conference Preview
Psych Congress: The Big Tent of Psychiatry
09/12/2025
Michael Asbach, DMSc, PA-C, shares what he is looking forward to at Psych Congress 2025.
Michael Asbach, DMSc, PA-C, shares what he is looking forward to at Psych Congress 2025.
Michael Asbach, DMSc, PA-C,...
09/12/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia
09/12/2025
Maria Mantas
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of...
09/12/2025
Psych Congress Network
fda building sign
News
FDA Approves TMS Device for Major Depressive Disorder in Adolescents
09/11/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug...
09/11/2025
Psych Congress Network
cannabis plant and CBD oil
News
High Levels of THC in Cannabis Products Associated With Mental Health Risks
09/11/2025
Maria Mantas
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained...
09/11/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Billing, Reimbursement, and Maximizing Revenue for Telehealth Services
09/09/2025
Edward Kaftarian, MD
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.
In this video, Psych Congress...
09/09/2025
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Shaping the Future of Schizophrenia Care With Muscarinic-Targeting Treatments
09/05/2025
Brooke Kempf, MSN, PMHNP-BC
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress...
09/05/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Hypersomnolence in Individuals With Mental Illness
09/05/2025
Craig Chepke, MD, DFAPA
Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.
Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.
Craig Chepke, MD, DFAPA,...
09/05/2025
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Navigating Regulations Regarding the Prescription of Controlled Substances via Telehealth
09/03/2025
Edward Kaftarian, MD
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych...
09/03/2025
Psych Congress Network
child embraces mother
News
Child Depression During COVID-19 Pandemic Associated With Subsequent Maternal Depression
09/02/2025
Maria Mantas
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and...
09/02/2025
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Early ADHD Drug Treatment Linked With Reduced Risk of Suicide, Substance Misuse, and Other Adverse Outcomes
08/27/2025
Jolynn Tumolo
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with...
08/27/2025
Psych Congress Network

Latest Expert Insights

Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 7: Sleep is the Foundation of Mental Health
09/12/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common,...
09/12/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Billing, Reimbursement, and Maximizing Revenue for Telehealth Services
09/09/2025
Edward Kaftarian, MD
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.
In this video, Psych Congress...
09/09/2025
Psych Congress Network
Podcasts
Psych Congress Family & Friends Podcast, Episode 6: Psychiatry Is the Specialty That Speaks for Those Without a Voice
09/08/2025
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than...
09/08/2025
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Shaping the Future of Schizophrenia Care With Muscarinic-Targeting Treatments
09/05/2025
Brooke Kempf, MSN, PMHNP-BC
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress...
09/05/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Hypersomnolence in Individuals With Mental Illness
09/05/2025
Craig Chepke, MD, DFAPA
Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.
Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.
Craig Chepke, MD, DFAPA,...
09/05/2025
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Navigating Regulations Regarding the Prescription of Controlled Substances via Telehealth
09/03/2025
Edward Kaftarian, MD
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych...
09/03/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 5: We’re Too Addicted to Our Own Good Ideas
08/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain...
08/25/2025
Psych Congress Network
Hara Oyedeji
Videos
Tackling Demographic Disparities in Schizophrenia Diagnosis
08/11/2025
Hara Oyedeji, APRN, PHMNP-BC, MS Ed
In this video, Psych Congress NP Institute Faculty Member Hara Oyedeji, APRN, PMHNP-BC, MSEd, discusses the demographic disparities that exist in the diagnosis of schizophrenia.
In this video, Psych Congress NP Institute Faculty Member Hara Oyedeji, APRN, PMHNP-BC, MSEd, discusses the demographic disparities that exist in the diagnosis of schizophrenia.
In this video, Psych Congress NP...
08/11/2025
Psych Congress Network

From the Newsrooms

Michael Asbach
Conference Preview
Psych Congress: The Big Tent of Psychiatry
09/12/2025
Michael Asbach, DMSc, PA-C, shares what he is looking forward to at Psych Congress 2025.
Michael Asbach, DMSc, PA-C, shares what he is looking forward to at Psych Congress 2025.
Michael Asbach, DMSc, PA-C,...
09/12/2025
Psych Congress Network
Brittany Albright and Kristian Dambrino
Clinical Pearls
Reconceptualizing Treatment-Resistant Depression as Monoamine Treatment-Resistant Depression
09/08/2025
Brittany Albright, MD, MPH; Kristian Dambrino, MSN, APRN, PMHNP
Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC, discuss the difference between major depressive disorder and treatment-resistant depression, plus monoaminergic versus glutamatergic treatments.
Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC, discuss the difference between major depressive disorder and treatment-resistant depression, plus monoaminergic versus glutamatergic treatments.
Brittany Albright, MD, MPH, and...
09/08/2025
Psych Congress NP Institute
Edward Kaftarian, MD
Videos
Navigating Regulations Regarding the Prescription of Controlled Substances via Telehealth
09/03/2025
Edward Kaftarian, MD
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych...
09/03/2025
Psych Congress Network
Desiree Matthews and Julie Carbray
APP Perspectives
A Strategic Approach to Billing Codes
08/19/2025
Desiree Matthews, PHMNP-BC; Julie A. Carbray, PhD, APRN
Julie Carbray, PhD, PMHNP-BC, APRN, and Desiree Matthews, PMHNP-BC, talk about some of the considerations surrounding billing and E&M codes
Julie Carbray, PhD, PMHNP-BC, APRN, and Desiree Matthews, PMHNP-BC, talk about some of the considerations surrounding billing and E&M codes
Julie Carbray, PhD, PMHNP-BC,...
08/19/2025
Psych Congress NP Institute
Desiree Matthews and Julie Carbray
APP Perspectives
Overcoming Documentation Challenges
08/12/2025
Desiree Matthews, PHMNP-BC; Julie A. Carbray, PhD, APRN
Julie Carbray, PhD, PMHNP-BC, APRN, and Desiree Matthews, PMHNP-BC, discuss common documentation challenges and talk about some of the potential ways to overcome them.
Julie Carbray, PhD, PMHNP-BC, APRN, and Desiree Matthews, PMHNP-BC, discuss common documentation challenges and talk about some of the potential ways to overcome them.
Julie Carbray, PhD, PMHNP-BC,...
08/12/2025
Psych Congress NP Institute
Hara Oyedeji
Videos
Tackling Demographic Disparities in Schizophrenia Diagnosis
08/11/2025
Hara Oyedeji, APRN, PHMNP-BC, MS Ed
In this video, Psych Congress NP Institute Faculty Member Hara Oyedeji, APRN, PMHNP-BC, MSEd, discusses the demographic disparities that exist in the diagnosis of schizophrenia.
In this video, Psych Congress NP Institute Faculty Member Hara Oyedeji, APRN, PMHNP-BC, MSEd, discusses the demographic disparities that exist in the diagnosis of schizophrenia.
In this video, Psych Congress NP...
08/11/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Practical Strategies for Building Patient Rapport Via Telehealth
08/07/2025
Edward Kaftarian, MD
In this video, Edward Kaftarian, MD, discusses effective strategies for building patient rapport via telehealth.
In this video, Edward Kaftarian, MD, discusses effective strategies for building patient rapport via telehealth.
In this video, Edward Kaftarian,...
08/07/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Considerations for Incorporating Muscarinic Agonists Into Schizophrenia Treatment
08/05/2025
Craig Chepke, MD, DFAPA
Psych Congress Elevate Co-Chair and Scientific Director Craig Chepke, MD, DFAPA, shares an overview of some of the most promising clinical findings regarding muscarinic receptor activators.
Psych Congress Elevate Co-Chair and Scientific Director Craig Chepke, MD, DFAPA, shares an overview of some of the most promising clinical findings regarding muscarinic receptor activators.
Psych Congress Elevate Co-Chair...
08/05/2025
Psych Congress Network
Desiree Matthews and Julie Carbray
APP Perspectives
A Closer Look at Documentation Practices
08/05/2025
Desiree Matthews, PHMNP-BC; Julie A. Carbray, PhD, APRN
Julie Carbray, PhD, PMHNP-BC, APRN, and Desiree Matthews, PMHNP-BC, discuss the main reasons why APPs take documentation in their practice and identify areas where improvement may be possible.
Julie Carbray, PhD, PMHNP-BC, APRN, and Desiree Matthews, PMHNP-BC, discuss the main reasons why APPs take documentation in their practice and identify areas where improvement may be possible.
Julie Carbray, PhD, PMHNP-BC,...
08/05/2025
Psych Congress NP Institute
Desiree Matthews
Videos
Anticipating Medication Interactions in Tardive Dyskinesia
08/01/2025
Desiree Matthews, PHMNP-BC
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC,...
08/01/2025
Psych Congress Network

Quizzes

Craig Chepke, MD, DFAPA
Quiz
Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia
09/12/2025
Maria Mantas
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of...
09/12/2025
Psych Congress Network
medication
Quiz
Test Your Knowledge: Study Results Link Non-Stimulant ADHD Therapy and Prescription Stimulant Misuse in Adolescents
09/09/2025
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about...
09/09/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge – Targeting Hyperactivity and Impulsivity in Adolescents: A Look at Viloxazine ER
09/04/2025
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of...
09/04/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge: Dr Rakesh Jain on Nonstimulant Treatment Options for Pediatric ADHD
09/03/2025
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the...
09/03/2025
Psych Congress Network
Wooden blocks spelling QUIZ
Quiz
Test Your Knowledge: Viloxazine ER Added to Stimulant Treatment for Pediatric ADHD Appears Safe, Effective
09/02/2025
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance...
09/02/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 3
Quiz
Test Your Knowledge – Navigating ADHD Care Forward: The Future of ADHD
08/27/2025
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test...
08/27/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 2
Quiz
Test Your Knowledge – Real-World Data Deep Dive: Viloxazine ER Compared With Atomoxetine for ADHD Study
08/25/2025
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER...
08/25/2025
Psych Congress Network
blocks spelling out the word "quiz"
Quiz
Initiating Clozapine in Patients With Schizophrenia
08/15/2025
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following...
08/15/2025
Psych Congress Network
Pharmacokinetics icon
Quiz
Test Your Knowledge – Pharmacokinetics of Viloxazine ER: What to Expect From Onset to Duration
08/12/2025
How well do you know the pharmacokinetics of viloxazine ER? Take this quiz to sharpen your clinical insight.
How well do you know the pharmacokinetics of viloxazine ER? Take this quiz to sharpen your clinical insight.
How well do you know the...
08/12/2025
Psych Congress Network
Hand blocking small red sad face buttons from large green smiling face button
Quiz
Test Your Knowledge – Viloxazine ER’s Impact on Comorbid Conditions: A Broader Approach to ADHD Management
08/12/2025
Discover how viloxazine ER is reshaping ADHD treatment—especially for patients with comorbid challenges—in this short clinical quiz.
Discover how viloxazine ER is reshaping ADHD treatment—especially for patients with comorbid challenges—in this short clinical quiz.
Discover how viloxazine ER is...
08/12/2025
Psych Congress Network

Recent FDA Updates

fda building sign
News
FDA Approves TMS Device for Major Depressive Disorder in Adolescents
09/11/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug...
09/11/2025
Psych Congress Network
FDA building
News
FDA Advisory Committee Votes Against Brexpiprazole Indication for Treatment of PTSD Following Efficacy Concerns
07/21/2025
Maria Mantas
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted not to recommend the use of brexpiprazole in combination with sertraline for the treatment of posttraumatic stress disorder (PTSD).  
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted not to recommend the use of brexpiprazole in combination with sertraline for the treatment of posttraumatic stress disorder (PTSD).  
The US Food and Drug...
07/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network

Live Meetings

Psych Congress Family & Friends Podcast

Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 7: Sleep is the Foundation of Mental Health
09/12/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common,...
09/12/2025
Psych Congress Network
Podcasts
Psych Congress Family & Friends Podcast, Episode 6: Psychiatry Is the Specialty That Speaks for Those Without a Voice
09/08/2025
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than...
09/08/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 5: We’re Too Addicted to Our Own Good Ideas
08/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain...
08/25/2025
Psych Congress Network
craig chepke and rakesh jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 4: Every Pill is a Choice
07/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
They are back! Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in...
They are back! Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in...
They are back! Through a...
07/25/2025
Psych Congress Network
Rakesh and Craig
Podcasts
Weighing the Options: Medication, Lifestyle, and the Path to Wellness
03/26/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain and Dr Craig Chepke explore medication-induced weight gain in schizophrenia treatment and how clinicians can help patients take control of their health, mind, and body.
In this episode, Dr Rakesh Jain...
03/26/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use